For the distinction between renal cell carcinomas and urothelial carcinomas, sensitivity was 86.7% and specificity 91.3% for PAX8, while sensitivity was 82.7% and specificity 99.8% for CDH16. This evidence concerns the gene PAX8 and hereditary clear cell renal cell carcinoma.